Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling

Cell Death & Differentiation volume 30, pages 1397–1399 (2023)Cite this article

Subjects

Perturbed proteostasis is an emerging hallmark of cancer, exhibiting aberrations in protein degradation by the ubiquitin-proteasome system (UPS) [1,2,3]. Numerous studies provide evidence that dysregulations in the activity of ubiquitin E3 ligases, which mediate the selective ubiquitination and subsequent degradation of critical cellular proteins, are associated with different aspects of tumorigenesis, cancer progression, tumor immune infiltration, and response to therapy [3]. Thus, understanding the molecular mechanisms that underlie such aberrations, and discovering the protein targets whose controlled degradation is perturbed in cancer, constitute an attractive area for cancer research. Such cancer-associated alterations in protein stability are becoming therapeutically targetable by the recent technologies in the targeted protein degradation (TPD) field and precision medicine [4, 5].

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Stabilization of EMSY in KEAP1-mutant NSCLC results in the inactivation of type I interferon signaling, reduction in DNA repair, and lowering of immune cell infiltration.

References

  1. Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Med. 2014;12:94.

    Google Scholar 

  2. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans. 2007;35:12–7.

    Article  CAS  PubMed  Google Scholar 

  3. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181:102–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma: the cancer genome atlas research network. Nature. 2014;511:543–50.

    Article  CAS  Google Scholar 

  7. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865:721–33.

    Article  CAS  PubMed  Google Scholar 

  8. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Papillon-Cavanagh S, Doshi P, Dobrin R, Szustakowski J, Walsh AM. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 2020;5:e000706.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Marzio A, Kurz E, Sahni JM, Di Feo G, Puccini J, Jiang S, et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell. 2022;185:169–83.

    Article  CAS  PubMed  Google Scholar 

  11. Byrum AK, Vindigni A, Mosammaparast N. Defining and modulating ‘BRCAness’. Trends Cell Biol. 2019;29:740–51.

    Article  CAS  PubMed  Google Scholar 

  12. Guo M, Wang SM. The BRCAness landscape of cancer. Cells. 2022;11:3877.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK. Differences in expression of key DNA damage repair genes after epigenetic-induced brcaness dictate synthetic lethality with PARP1 inhibition. Mol Cancer Ther. 2015;14:2321–31.

    Article  CAS  PubMed  Google Scholar 

  14. Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opin Ther Targets. 2019;23:773–85.

    Article  CAS  PubMed  Google Scholar 

  15. Jelinic P, Eccles LA, Tseng J, Cybulska P, Wielgos M, Powell SN, et al. The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair. Oncotarget. 2017;8:13792–804.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Livingston DM. EMSY, a BRCA-2 partner in crime. Nat Med. 2004;10:127–8.

    Article  CAS  PubMed  Google Scholar 

  17. Ezell SA, Tsichlis PN. Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response. Transcription. 2012;3:305–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, et al. The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci USA 2012;109:E613–621.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18:152.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding

YM is funded by the European Research Council (ERC- CoG - grant agreement No. 101045613); the Melanoma Research Alliance (MRA - grant agreement No. 826874) and the Cancer Research Institute/Israel Cancer Research Fund CLIP Grant (CRI4351).

Author information

Authors and Affiliations

  1. Department of Systems Immunology, Weizmann Institute of Science, Rehovot, 7610001, Israel

    Daoud Sheban & Yifat Merbl

Authors
  1. Daoud Sheban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yifat Merbl
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DS and YM wrote the paper and prepared the figure.

Corresponding author

Correspondence to Yifat Merbl.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheban, D., Merbl, Y. EMSY stabilization in KEAP1-mutant lung cancer disrupts genome stability and type I interferon signaling. Cell Death Differ 30, 1397–1399 (2023). https://doi.org/10.1038/s41418-023-01150-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41418-023-01150-z

Search

Advanced search

Quick links